share_log

Replimune Begins RP2 Clinical Trials With First Patients Enrolled In Metastatic Uveal Melanoma And Hepatocellular Carcinoma

Benzinga ·  Jan 8 21:08

Advancing Its Oncolytic Immunotherapy Platform Following RP1 BLA Submission And Breakthrough Therapy Designation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment